Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
64.71
+0.16 (0.25%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Arcellx Employees
Arcellx had 163 employees as of December 31, 2024. The number of employees increased by 33 or 25.38% compared to the previous year.
Employees
163
Change (1Y)
33
Growth (1Y)
25.38%
Revenue / Employee
$662,184
Profits / Employee
-$658,577
Market Cap
3.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 163 | 33 | 25.38% |
| Dec 31, 2023 | 130 | 32 | 32.65% |
| Dec 31, 2022 | 98 | 20 | 25.64% |
| Dec 31, 2021 | 78 | 47 | 151.61% |
| Dec 31, 2019 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ACLX News
- 15 hours ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha
- 15 hours ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 5 weeks ago - Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire
- 6 weeks ago - Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - GlobeNewsWire
- 6 weeks ago - Arcellx Impressive Safety Data Leaves Doubts - Seeking Alpha
- 2 months ago - Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 5 months ago - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Benzinga